Cancer care is moving toward a more individualized future, where treatment decisions increasingly consider the unique biological characteristics of each patient’s disease. Thomas H. Jensen, CEO of Allarity Therapeutics, believes drug development and diagnostics must progress together to support this evolution. Through its precision medicine platform and Drug Response Predictor (DRP) technology, Allarity Therapeutics focuses on connecting patients with therapies that may offer the greatest potential benefit based on tumor biology.
Jensen’s career has focused on the relationship between advanced science, laboratory innovation, and bioinformatics. As CEO of Allarity Therapeutics, he guides the company’s efforts in developing personalized cancer therapies, with particular focus on stenoparib, a clinical-stage oncology program being studied for advanced ovarian cancer. His background includes extensive work in computational biology and predictive diagnostics, areas that have informed Allarity’s development of its DRP platform, which analyzes gene expression patterns to help identify patients who may respond to specific treatments.
His perspective on oncology is influenced by years of examining how biological complexity affects treatment outcomes. Jensen views precision medicine as a field where deeper understanding of tumor biology can support more informed decisions throughout the drug development process.
“Cancer biology is incredibly complex, and the future belongs to tools that respect that complexity by allowing the data from each patient’s tumor to guide decisions,” Jensen states. “The opportunity is to create a stronger connection between the science behind a medicine and the patients who may benefit from it.”
This perspective reflects a broader transformation taking place across oncology. The American Association for Cancer Research (AACR) Cancer Progress Report highlights how precision medicine has expanded beyond traditional treatment models by incorporating biological characteristics that distinguish individual patients, including genomic, transcriptomic, immune, metabolic, and protein-related information. The report describes cancer as a disease influenced by a combination of biological, environmental, lifestyle, and other factors, creating opportunities for more personalized strategies.
For Jensen, this evolution reinforces the importance of predictive diagnostics as an essential component of modern therapeutic development. Drug discovery has traditionally focused heavily on identifying promising molecules, while precision oncology adds another dimension: understanding which patients are most likely to benefit from those therapies.
“The future of oncology is built around matching the right therapy with the right patient at the right time. A medicine’s potential is connected to the biological profile of the patients receiving it, and predictive technologies help us explore that relationship,” Jensen says.
Allarity’s DRP technology reflects this philosophy by using tumor gene expression data and systems biology analysis to identify patterns associated with drug response. The platform has been developed to support patient selection in clinical development, helping researchers investigate therapies within patient groups that may share relevant biological characteristics.
This model aligns with the growing role of companion diagnostics in oncology. Research and Markets’ Oncology Companion Diagnostic Market report projects continued growth in this sector, citing increasing interest in biomarker-guided treatment selection and personalized healthcare.
The expansion of personalized medicine also highlights the importance of high-quality, diverse data. The AACR Cancer Progress Report notes that initiatives such as AACR Project GENIE have expanded access to large-scale cancer datasets, with tumor sequencing information from more than 227,000 patients across multiple international cancer centers. These resources are helping researchers explore cancer biology across broader patient populations while supporting efforts to improve representation in precision medicine research.
As these scientific advances continue, Jensen believes the value of oncology innovation extends beyond initial tumor response. He emphasizes the importance of considering longer-term patient outcomes when evaluating treatment potential. “A reduction in tumor size can provide important information, but the ultimate goal of cancer therapy is to help patients live longer and maintain their quality of life,” he emphasizes. “The most meaningful advances come from connecting biological insight with outcomes that matter to patients.”
This philosophy informs Allarity’s development strategy around stenoparib, an orally available small molecule designed to inhibit PARP and tankyrase pathways. The company is studying stenoparib in advanced ovarian cancer while applying its DRP companion diagnostic to support patient selection. The program has received Fast Track designation from the FDA for advanced ovarian cancer, reflecting regulatory recognition of the need for continued development in this area.
The integration of artificial intelligence, biomarker research, and predictive diagnostics may further influence oncology’s next phase. Jensen sees opportunities for AI-driven tools to expand analysis capabilities, while also recognizing the importance of reliable biological datasets and rigorous scientific validation. He says, “Technology creates possibilities, but meaningful progress depends on understanding the biology behind the data. The combination of scientific expertise, advanced analytics, and patient-specific information can help build a more connected model of cancer care.”
Ultimately, as precision medicine continues to develop, personalized treatment selection is becoming an increasingly important element of oncology research and clinical practice. For companies such as Allarity Therapeutics, the focus remains on advancing technologies that connect therapeutic innovation with deeper biological understanding. Jensen’s vision reflects a future where diagnostics and therapeutics develop in partnership, creating pathways for more tailored cancer treatment strategies and supporting the continued advancement of patient-focused oncology.
